Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results
- Agreement reached with Merck KGaA to gain back the full rights of NMS-293
- Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS will expand clinical development of NMS-293 beyond the ongoing Phase 2 study in combination with temozolomide in patients with relapsed glioblastoma.
NERVIANO, Italy, November 25 2024 – Nerviano Medical Sciences S.r.l. (NMS), a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that it has successfully negotiated with Merck KGaA the buy back of the full world-wide rights of NMS-293 (also known as NMS-03305293).
NMS-293 is a potent, highly selective PARP1 inhibitor designed to avoid trapping, a known cause of toxicity in healthy cells, making it ideal for combination with DNA-damaging agents like chemotherapies, or ADC payloads, including in homologous recombination repair proficient tumors. In this respect, initial safety data across the program have shown high bone marrow tolerability1, supporting future promising clinical combinations in solid tumors.
Hugues Dolgos, Pharm.D., Chief Executive Officer, NMS commented: “The agreement that we announce today allows Nerviano Medical Sciences to re-gain full control of NMS-293, an innovative potential treatment for cancer patients, which we believe offers opportunity beyond the ongoing phase 2 study in patients with relapsed glioblastoma. We thank our partner Merck KGaA for the excellent collaboration. Our team is actively preparing two phase 1/2 trials to explore solid tumors, which will be subject to a further communication”
Link PR: PR_NMS_NMS-MRK PR
- Guerts et al. AACR-NCI-EORTC 2023. Initial results from 2 Phase 1 studies of NMS-03305293, a selective PARP1 inhibitor.
